Supplementary Figure 5 from An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
crossref(2023)
Abstract
PDF file - 237K, Figure S5. Combination treatment consisting of trastuzumab+LJM716 or Cetuximab+LJM716 is well tolerated.
Translated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined